<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122537">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01698372</url>
  </required_header>
  <id_info>
    <org_study_id>KCI VAC Study</org_study_id>
    <nct_id>NCT01698372</nct_id>
  </id_info>
  <brief_title>Negative Pressure Dressing After Saphenous Vein Harvest</brief_title>
  <official_title>Negative Pressure Dressing to Decrease the Incidence of Leg Wound Complications After CABG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCI USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the effectiveness of negative pressure wound therapy (using the VAC
      Prevena device, KCI Canada Inc.) applied to the saphenous vein harvest site after Coronary
      Artery Bypass Grafting (CABG).  When initiated immediately after surgery, this intervention
      may decrease the incidence of wound infection and non-infectious wound complications.  It
      may decrease wound discomfort and improve mobility and functional recovery of the leg.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Change from baseline ASEPSIS score of wound healing at 6 weeks.</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The ASEPSIS quantitative wound scoring method will be used to assess patients' leg wound healing after saphenous vein harvesting for coronary artery bypass surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total score of pain level.</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be asked to evaluate the level of pain (using the Leg Incision Assessment Form) at the wound site after saphenous vein harvesting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Complication of Coronary Artery Bypass Graft</condition>
  <condition>Wound Complication</condition>
  <arm_group>
    <arm_group_label>Prevena device (Group A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A will have the VAC Prevena portable device applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional dressing (Group B)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group B will have conventional dry dressing applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prevena device  (Group A)</intervention_name>
    <description>This portable device is applied to initiate negative pressure therapy to a wound site.</description>
    <arm_group_label>Prevena device (Group A)</arm_group_label>
    <other_name>Prevena Incision Management System</other_name>
    <other_name>Prevena 125</other_name>
    <other_name>PRE1001.S Prevena Incision Kit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting for elective or semi-elective isolated first-time CABG  surgery
             with harvesting of the greater saphenous vein.

          -  Must be 18 years or older.

          -  Must live with one hour driving distance from Calgary.

          -  Must provide written consent.

        Exclusion Criteria:

          -  Previous CABG surgery or previous lower leg surgical intervention.

          -  In emergent need for surgery.

          -  Have severe peripheral vascular disease.

          -  Do not speak and read the English language.

          -  Have dialysis-dependent renal failure.

          -  Require chronic steroids.

          -  Unable to return to clinic for follow-up due to functional or cognitive impairment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Fedak, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Fedak, MD, PhD</last_name>
    <phone>403-944-5931</phone>
    <email>paul.fedak@albertahealthservices.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda B Andersen, PhD</last_name>
    <phone>403-944-8076</phone>
    <email>lbanders@ucalgary.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Libin Cardiovascular Institute, Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Fedak, MD, PhD</last_name>
      <phone>403-944-5931</phone>
      <email>paul.fedak@albertahealthservices.ca</email>
    </contact>
    <contact_backup>
      <last_name>Linda B Andersen, PhD</last_name>
      <phone>403-944-8076</phone>
      <email>lbanders@ucalgary.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Fedak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 28, 2012</lastchanged_date>
  <firstreceived_date>September 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Dr. Paul Fedak</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Cardiac surgery.</keyword>
  <keyword>Wound healing.</keyword>
  <keyword>Leg wound infection.</keyword>
  <keyword>Wound care.</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
